Result-oriented scientist with background in development, clinical research, various healthcare settings, well-versed in both cosmetic, pharmaceutical and biopharmaceutical industry. Knowledgeable about action planing, GCP, GMP, ICH, database lock and standard operating system
NIH:ICH-GCP (E6R2) (10/2020)
The CRA Academy (8/2020)
IATA-Dangerious goods training (8/2019)
Phase 3 Study of Sacituzumab Govitecan versus treatment of Physician's Choice in subjects with HR+ HER2- Mestastatic Breast Cancer (MBC).
A Phase 1 Dose-Escalation Study of XXX with XXX and XXX in the Neoadjuvant Setting in Previously Untreated Patients with ER+/HER2- Breast Cancer